

IN THE CLAIMS:

Kindly Amend Claims 1-7, 9, 11-12 and 16-17 as follows:

1. (Currently Amended) An intravaginal drug delivery device for administration into a vaginal environment, the device comprising at least one reservoir, ~~the, or each,~~ the at least one reservoir containing at least one pharmacologically active agent or a prodrug thereof, dispersed in a ~~carrier system~~ hydrophobic elastomeric polymer; and a sheath discontinuously surrounding the at least one reservoir, so that, in use, at least part of the at least one reservoir is directly exposed to the vaginal environment.

2. (Currently Amended) An intravaginal drug delivery device according to Claim 1, in which the sheath defines at least one hole or opening, ~~one or more holes or openings,~~ ~~the, or each,~~ at least one hole or opening extending through the sheath to the at least one reservoir, so that at least part of the at least one reservoir is exposed, in use, to the vaginal environment.

3. (Currently Amended) An intravaginal drug delivery device according to Claim 2, in which the, ~~or each,~~ at least one hole or opening extends to the surface of the at least one reservoir and/or extends partially into the at least one reservoir.

4. (Currently Amended) An intravaginal drug delivery device according to Claim 2, in which the, ~~or each,~~ at least one hole or opening is ~~of any a shape or is joined with an adjacent hole or opening to give a continuous opening in the form of a slit.~~

5. (Currently Amended) An intravaginal drug delivery device according to Claim 2, in which the ~~the, or each,~~ at least one hole or opening is substantially cylindrical with a diameter in the range of about 0.5 to 6.5 mm.

6. (Currently Amended) An intravaginal drug delivery device according to Claim 2, in which the ~~the, or each,~~ at least one hole or opening extends through the sheath substantially normal to the reservoir surface.

7. (Currently Amended) An intravaginal drug delivery device according to Claim 2, in which the device is a ring that is substantially circular in transverse cross-section, and the ~~the, or each,~~ at least one hole extends substantially radially, ~~inwardly or outwardly,~~ through the sheath at the inner circumference of the ring or at outer circumference of the ring.

8. (Previously Amended) An intravaginal drug delivery device according to Claim 7, in which there are one to thirty of said holes along the inner or outer circumference of the intravaginal drug delivery device.

9. (Currently Amended) An intravaginal drug delivery device according to Claim 2, in which the device is a substantially cylindrical rod device, and said ~~holes are~~ at least one hole or opening is provided at each terminal end of the rod.

10. (Original) An intravaginal drug delivery device according to Claim 9, in which the rod device defines a right circular cylinder and each base of the rod is partly or fully exposed, to define said holes.

11. (Currently Amended) An intravaginal drug delivery device according to Claim 9, in which further holes or ~~slits~~ openings are provided extending substantially radially through the sheath.

12. (Currently Amended) An intravaginal drug delivery device according to Claim 11, in which there are one to thirty of said further holes or openings, along the circumference of the rod.

13. (Previously Amended) An intravaginal drug delivery device according to Claim 1, in which the device is a partial or complete toroid shape.

14. (Previously Amended) An intravaginal drug delivery device according to Claim 1, in which the reservoir additionally comprises at least one pore-forming excipient.

15. (Previously Amended) An intravaginal drug delivery device according to Claim 14, in which the pore-forming excipient comprises a water-soluble or water-swellaable polysaccharide, a monosaccharide or a disaccharide, water-soluble salt; a protein; a nonionic surface active agent; a bile salt; an organic solvent, or a fatty acid ester.

16. (Currently Amended) An intravaginal drug delivery device according to Claim 1, in which the sheath ~~additionally~~ comprises at least one additional pharmacologically active agent.

17. (Currently Amended) A method of manufacturing an intravaginal drug delivery device according to Claim 1, said method comprising the steps of forming a reservoir by dispersing at least one pharmacologically active agent in a pharmaceutically acceptable ~~carrier~~

~~system~~ hydrophobic elastomeric polymer; curing the reservoir; and applying a sheath to partly surround the reservoir.

18. (Previously Amended) A method of manufacturing an intravaginal drug delivery device according to Claim 1, said method comprising injecting or extruding a reservoir material into a hollow sheath.